<p>Day One Biopharmaceuticals has completed its acquisition of Mersana Therapeutics, expanding its pipeline with the addition of emiltatug ledadotin (Emi-Le), a clinical-stage antibody drug conjugate targeting the rare cancer adenoid cystic carcinoma (ACC). The transaction includes a payment of $25 per Mersana share in cash, plus a non-tradable contingent value right (CVR) per share, offering potential milestone payments of up to $30.25 per CVR. This move strengthens Day One’s focus on rare cancers and adult oncology, adding a second novel ADC to its clinical pipeline and building on the momentum of its marketed therapies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Day One Biopharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620634-en) on January 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics